What is a primary treatment option for ITP?

In treating Immune Thrombocytopenic Purpura (ITP), corticosteroids, such as prednisone, are a primary treatment option because they help to increase platelet counts by reducing the immune system's attack on platelets. Steroids work by suppressing the immune response that leads to the destruction of platelets in the spleen and are often the first-line therapy for patients with ITP, particularly in cases where mild to moderate thrombocytopenia is present.

In contrast, platelet transfusions are not effective in this condition because the underlying problem is not a lack of platelets but rather the destruction of platelets by the immune system. Anticoagulants are used to prevent clotting and would not be appropriate in managing ITP as they could potentially worsen bleeding risk due to low platelet counts. Antiplatelet medications, which are designed to prevent platelets from aggregating, would similarly be contraindicated in ITP as they could contribute to a decrease in platelet function and further complicate the patient's bleeding risk. Thus, corticosteroids remain a key therapeutic approach for effectively managing ITP and improving platelet counts.